FGF21 has substantial promise as a novel biomarker as its circulating level gives an insight into several pathophysiological processes, such as oxidative stress, cardiac hypertrophy, and inflammation, that are involved in HF [24, 25]. The gene discussed is FGF21; the disease is cardiac hypertrophy.